Top

Published in:

01-07-2020 | Acromegaly | Topic Review

Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes

Authors: Raj Singh, Prabhanjan Didwania, Eric J. Lehrer, Darrah Sheehan, Kimball Sheehan, Daniel M. Trifiletti, Jason P. Sheehan

Published in: Journal of Neuro-Oncology | Issue 3/2020

Abstract

Introduction

We performed a systematic review and meta-analysis of clinical outcomes for patients with acromegaly treated with stereotactic radiosurgery (SRS).

Methods

Primary outcomes were 5- and 10-year endocrine remission (ER) and endocrine control (EC). Secondary outcomes were 10-year radiographic local control (LC), visual toxicity, and hypopituitarism rates. Weighted random effects meta-analyses using the DerSimonian and Laird methods were conducted to characterize and compare effect sizes. Mixed effects regression models were used to examine correlations between potential prognostic factors and primary and secondary outcomes.

Results

In total, 1533 patients across 20 published studies with acromegaly treated with SRS were included. At 5-years, estimated ER and EC rates were 43.2% (95% CI 31.7–54.6%) and 55.0% (95% CI 27.6–82.4%), respectively. At 10-years, estimated ER and EC rates were 56.9% (95% CI 47.5–66.4%) and 69.7% (95% CI 47.7–91.8%), respectively. The estimated 10-year LC rate was 92.8% (95% CI 83.0–100%). Visual toxicity and hypopituitarism following SRS were estimated to be 2.7% (95% CI 1.3–4.2%) and 26.8% (95% CI 16.9–36.7%), respectively. Every 1 Gy increase in margin prescription dose beyond 17 Gy was estimated to result in a 0.41% increased risk of visual toxicity (p = 0.03). No prognostic factors were associated with EC, ER, LC, or hypopituitarism.

Conclusions

SRS was well-tolerated in the management of pituitary acromegaly resulting in gradually improving ER and EC rates over time that approached 60% and 70%. SRS-related visual loss is an uncommon treatment-related side effect, and patient-specific clinical decision making remains critical.

Available only for authorised users

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62. https://doi.org/10.1093/neuonc/nov189CrossRefPubMedPubMedCentral

Mehta GU, Lonser RR (2017) Management of hormone-secreting pituitary adenomas. Neuro Oncol 19(6):762–773. https://doi.org/10.1093/neuonc/now130CrossRefPubMed

Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura E, Silva L, Agra R, Pontes L, Montenegro L, Albuquerque JL, Canadas V (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary 13(2):123–129. https://doi.org/10.1007/s11102-009-0209-8CrossRefPubMed

Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509–1517. https://doi.org/10.1210/jc.2008-2421CrossRefPubMed

Molitch ME (2008) Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin N Am. 37(1):151–171. https://doi.org/10.1016/j.ecl.2007.10.011CrossRef

Platta CS, Mackay C, Welsh JS (2010) Pituitary adenoma: a radiotherapeutic perspective. Am J Clin Oncol 33(4):408–419. https://doi.org/10.1097/COC.0b013e31819d878dCrossRefPubMed

Chole RA, Lim C, Dunham B, Chicoine MR, Dacey RG Jr (2011) A novel transnasal transsphenoidal speculum: a design for both microscopic and endoscopic transsphenoidal pituitary surgery. J Neurosurg 114(5):1380–1385. https://doi.org/10.3171/2010.11.JNS101167CrossRefPubMed

Laws ER, Sheehan JP, Sheehan JM, Jagnathan J, Jane JA Jr, Oskouian R (2004) Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol 69(1–3):257–272CrossRef

Abu Dabrh AM, Asi N, Farah WH, Mohammed K, Wang Z, Farah MH, Prokop LJ, Katznelson L, Murad MH (2015) Endocr Pract 21(8):943–956. https://doi.org/10.4158/EP14574.ORCrossRefPubMed

10.

Ding D, Mehta GU, Patibandla MR, Lee CC, Liscak R, Kano H, Pai FY, Kosak M, Sisterson ND, Martinez-Alvarez R, Martinez-Moreno N, Mathieu D, Grills IS, Blas K, Lee K, Cifarelli CP, Katsevman GA, Lee JYK, McShane B, Kondziolka D, Lunsford LD, Vance ML, Sheehan JP (2019) Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study. Neurosurgery 84(3):717–725. https://doi.org/10.1093/neuros/nyy178CrossRefPubMed

11.

Knappe UJ, Petroff D, Quinkler M, Schmid SM, Schöfl C, Schopohl J, Stieg MR, Tönjes A (2020) Participants of the German Acromegaly Registry. Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry. Eur J Endocrinol 182(3):275–284. https://doi.org/10.1530/eje-19-0784CrossRefPubMed

12.

Richardson WS, Wilson MC, Nishikawa J, Hayward RS (1995) The well-built clinical question: a key to evidence-based decisions. ACP J Club 123(3):A12–A13PubMed

13.

Ebell M (1999) Information at the point of care: answering clinical questions. J Am Board Fam Pract 12:225–235CrossRef

14.

Huang X, Lin J, Demner-Fushman D (2006) Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc, pp 359-63

15.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e10000097CrossRef

16.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):200–212CrossRef

17.

Team R (2015) RStudio: integrated development environment for R

18.

Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36:1–48CrossRef

19.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRef

20.

Ades AE, Lu G, Higgins JP (2005) The interpretation of random-effects meta-analysis in decision models. Med Decis Making 25:646–654CrossRef

21.

Fleiss JL, Gross AJ (1991) Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 44:127–139CrossRef

22.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRef

23.

Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:110–129

24.

Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M (2003) Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 88(7):3105–3112CrossRef

25.

Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, Conte-Devolx B, Régis J, Dufour H, Brue T (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90(8):4483–4488CrossRef

26.

Erdur FM, Kilic T, Peker S, Celik O, Kadioglu P (2011) Gammaknife radiosurgery in patients with acromegaly. J Clin Neurosci 18(12):1616–1620. https://doi.org/10.1016/j.jocn.2011.03.023CrossRefPubMed

27.

Gutt B, Wowra B, Alexandrov R, Uhl E, Schaaf L, Stalla GK, Schopohl J (2005) Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly. Exp Clin Endocrinol Diabetes 113(4):219–224CrossRef

28.

Ikeda H, Jokura H, Yoshimoto T (2001) Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma. J Neurosurg 95(2):285–291CrossRef

29.

Jezková J, Marek J, Hána V, Krsek M, Weiss V, Vladyka V, Lisák R, Vymazal J, Pecen L (2006) Gamma knife radiosurgery for acromegaly–long-term experience. Clin Endocrinol (Oxf) 64(5):588–595CrossRef

30.

Liu X, Kano H, Kondziolka D, Park KJ, Iyer A, Niranjan A, Flickinger JC, Lunsford LD (2012) Gamma knife radiosurgery for clinically persistent acromegaly. J Neurooncol 109(1):71–79. https://doi.org/10.1007/s11060-012-0862-zCrossRefPubMed

31.

Pai FY, Chen CJ, Wang WH, Yang HC, Lin CJ, Wu HM, Lin YC, Chen HS, Yen YS, Chung WY, Guo WY, Pan DH, Shiau CY, Lee CC (2019) Low-dose gamma knife radiosurgery for acromegaly. Neurosurgery 85(1):E20–E30. https://doi.org/10.1093/neuros/nyy410CrossRefPubMed

32.

Pollock BE, Jacob JT, Brown PD, Nippoldt TB (2007) Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 106(5):833–838CrossRef

33.

Poon TL, Leung SC, Poon CY, Yu CP (2010) Predictors of outcome following Gamma Knife surgery for acromegaly. J Neurosurg 113(Suppl):149–152CrossRef

34.

Ronchi CL, Attanasio R, Verrua E, Cozzi R, Ferrante E, Loli P, Montefusco L, Motti E, Ferrari DI, Giugni E, Beck-Peccoz P, Arosio M (2009) Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study. Clin Endocrinol (Oxf) 71(6):846–852. https://doi.org/10.1111/j.1365-2265.2009.03589.xCrossRef

35.

Vik-Mo EO, Oksnes M, Pedersen PH, Wentzel-Larsen T, Rødahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M (2007) Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 157(3):255–263CrossRef

36.

Sims-Williams HP, Rajapaksa K, Sinha S, Radatz M, Walton L, Yianni J, Newell-Price J (2019) Radiosurgery as primary management for acromegaly. Clin Endocrinol (Oxf) 90(1):114–121. https://doi.org/10.1111/cen.13870CrossRef

37.

Lee CC, Vance ML, Xu Z, Yen CP, Schlesinger D, Dodson B, Sheehan J (2014) Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 99(4):1273–1281. https://doi.org/10.1210/jc.2013-3743CrossRefPubMed

38.

Wilson PJ, De-Loyde KJ, Williams JR, Smee RI (2013) Acromegaly: a single centre’s experience of stereotactic radiosurgery and radiotherapy for growth hormone secreting pituitary tumours with the linear accelerator. J Clin Neurosci. 20(11):1506–1513. https://doi.org/10.1016/j.jocn.2012.11.026CrossRefPubMed

39.

Kong DS, Kim YH, Kim YH, Hur KY, Kim JH, Kim MS, Paek SH, Kwon DH, Kim DK, Lee JI (2019) Long-term efficacy and tolerability of gamma knife radiosurgery for growth hormone-secreting adenoma: a retrospective multicenter study (MERGE-001). World Neurosurg 122:e1291–e1299. https://doi.org/10.1016/j.wneu.2018.11.038CrossRefPubMed

40.

Iwata H, Sato K, Nomura R, Tabei Y, Suzuki I, Yokota N, Inoue M, Ohta S, Yamada S, Shibamoto Y (2016) Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus. J Neurooncol 128(2):267–275. https://doi.org/10.1007/s11060-016-2105-1CrossRefPubMed

41.

Boström JP, Kinfe T, Meyer A, Pintea B, Gerlach R, Surber G, Lammering G, Hamm K (2015) Treatment of acromegaly patients with risk-adapted single or fractionated stereotactic high-precision radiotherapy: high local control and low toxicity in a pooled series. Strahlenther Onkol 191(6):477–485. https://doi.org/10.1007/s00066-014-0802-2CrossRefPubMed

42.

Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM (2005) The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol 62(2):210–216. https://doi.org/10.1111/j.1365-2265.2005.02199.xCrossRef

43.

Minniti G, Osti MF, Niyazi M (2016) Target deliniation and optimalradiosurgical dose for pituitary tumors. Radiat Oncol 11(1):135. https://doi.org/10.1186/s13014-016-0710-yCrossRefPubMedPubMedCentral

44.

Taylor DG, Janssen A, Ding D, Xu Z, Mehta GU, Liscak R, Kano H, Kosak M, Martinez-Morano N, Hobbs L, Chen CJ, Grills IS, Mathieu D, Lunsford LD, Vance ML, Sheehan JP (2020) Whole sella vs. targeted stereotactic radiosurgery for acromegaly: a multicenter match cohort study. Neurosurgery 86(5):656–664. https://doi.org/10.1093/neuros/nyz245CrossRefPubMed

45.

Wattson DA, Tanguturi SK, Spiegel DY, Niemierko A, Biller BM, Nachtigall LB, Bussière MR, Swearingen B, Chapman PH, Loeffler JS, Shih HA (2014) Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 90:532–539. https://doi.org/10.1016/j.ijrobp.2014.06.068CrossRefPubMed

46.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634CrossRef

Title: Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes
Authors: Raj Singh
Prabhanjan Didwania
Eric J. Lehrer
Darrah Sheehan
Kimball Sheehan
Daniel M. Trifiletti
Jason P. Sheehan
Publication date: 01-07-2020
Publisher: Springer US
Keywords: Acromegaly
Radiotherapy
Hypopituitarism
Published in: Journal of Neuro-Oncology / Issue 3/2020
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03552-2

At a glance: The STEP trials

Springer Medicine

Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

PARP inhibition suppresses the emergence of temozolomide resistance in a model system

Laser interstitial thermal therapy (LITT) vs. bevacizumab for radiation necrosis in previously irradiated brain metastases

Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial

Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study

Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial

Long-term survival outcomes of pineal region gliomas